Novo Nordisk, a global healthcare company, agreed to acquire the development and manufacturing facility in Athlone, Ireland from Alkermes, a global biopharmaceutical company, for $93m. "The acquisition of the Athlone facility represents an expansion of Novo Nordisk's global manufacturing setup and will provide Novo Nordisk with additional development and manufacturing capacity for current and future oral products. With this acquisition, we are excited to soon welcome approximately 400 highly skilled colleagues currently employed by Alkermes with valuable capabilities within oral drug development and manufacturing who will play a key role in serving even more patients with oral products," Thilde G. Hummel Bøgebjerg, Novo Nordisk Senior Vice President, Product Supply Emerging Technologies.